Literature DB >> 23500087

Uptake and outcomes of intensity-modulated radiation therapy for uterine cancer.

Jason D Wright1, Israel Deutsch, Elizabeth T Wilde, Cande V Ananth, Alfred I Neugut, Sharyn N Lewin, Zainab Siddiq, Thomas J Herzog, Dawn L Hershman.   

Abstract

OBJECTIVE: While intensity-modulated radiation therapy (IMRT) allows more precise radiation planning, the technology is substantially more costly than conformal radiation and, to date, the benefits of IMRT for uterine cancer are not well defined. We examined the use of IMRT and its effect on late toxicity for uterine cancer.
METHODS: Women with uterine cancer treated from 2001 to 2007 and registered in the SEER-Medicare database were examined. We investigated the extent and predictors of IMRT administration. The incidence of acute and late-radiation toxicities was compared for IMRT and conformal radiation.
RESULTS: We identified a total of 3555 patients including 328 (9.2%) who received IMRT. Use of IMRT increased rapidly and reached 23.2% by 2007. In a multivariable model, residence in the western U.S. and receipt of chemotherapy were associated with receipt of IMRT. Women who received IMRT had a higher rate of bowel obstruction (rate ratio=1.41; 95% CI, 1.03-1.93), but other late gastrointestinal and genitourinary toxicities as well as hip fracture rates were similar between the cohorts. After accounting for other characteristics, the cost of IMRT was $14,706 (95% CI, $12,073 to $17,339) greater than conformal radiation.
CONCLUSION: The use of IMRT for uterine cancer is increasing rapidly. IMRT was not associated with a reduction in radiation toxicity, but was more costly.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23500087      PMCID: PMC3903584          DOI: 10.1016/j.ygyno.2013.03.006

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  35 in total

1.  Estimating health care costs related to cancer treatment from SEER-Medicare data.

Authors:  Martin L Brown; Gerald F Riley; Nicki Schussler; Ruth Etzioni
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size.

Authors:  Anesa Ahamad; Warren D'Souza; Mohammad Salehpour; Revathy Iyer; Susan L Tucker; Anuja Jhingran; Patricia J Eifel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-15       Impact factor: 7.038

3.  A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis.

Authors:  Jean-Philippe Pignol; Ivo Olivotto; Eileen Rakovitch; Sandra Gardner; Katharina Sixel; Wayne Beckham; Thi Trinh Thuc Vu; Pauline Truong; Ida Ackerman; Lawrence Paszat
Journal:  J Clin Oncol       Date:  2008-02-19       Impact factor: 44.544

4.  Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer.

Authors:  William Small; Loren K Mell; Penny Anderson; Carien Creutzberg; Jennifer De Los Santos; David Gaffney; Anuja Jhingran; Lorraine Portelance; Tracey Schefter; Revathy Iyer; Mahesh Varia; Kathryn Winter; Arno J Mundt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-26       Impact factor: 7.038

5.  A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.

Authors:  Howard D Homesley; Virginia Filiaci; Susan K Gibbons; Harry J Long; David Cella; Nick M Spirtos; Robert T Morris; Koen DeGeest; Roger Lee; Anthony Montag
Journal:  Gynecol Oncol       Date:  2008-12-23       Impact factor: 5.482

6.  Evaluation of trends in the cost of initial cancer treatment.

Authors:  Joan L Warren; K Robin Yabroff; Angela Meekins; Marie Topor; Elizabeth B Lamont; Martin L Brown
Journal:  J Natl Cancer Inst       Date:  2008-06-10       Impact factor: 13.506

7.  Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients.

Authors:  Michael K M Kam; Sing-Fai Leung; Benny Zee; Ricky M C Chau; Joyce J S Suen; Frankie Mo; Maria Lai; Rosalie Ho; Kin-yin Cheung; Brian K H Yu; Samuel K W Chiu; Peter H K Choi; Peter M L Teo; Wing-hong Kwan; Anthony T C Chan
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

8.  The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.

Authors:  Angeles Alvarez Secord; Laura J Havrilesky; Victoria Bae-Jump; Jeanette Chin; Brian Calingaert; Amy Bland; Teresa L Rutledge; Andrew Berchuck; Daniel L Clarke-Pearson; Paola A Gehrig
Journal:  Gynecol Oncol       Date:  2007-08-06       Impact factor: 5.482

9.  Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer.

Authors:  Xianglin L Du; Shenying Fang; Sally W Vernon; Hashem El-Serag; Y Tina Shih; Jessica Davila; Monica L Rasmus
Journal:  Cancer       Date:  2007-08-01       Impact factor: 6.860

Review 10.  Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis.

Authors:  P Blake; Ann Marie Swart; J Orton; H Kitchener; T Whelan; H Lukka; E Eisenhauer; M Bacon; D Tu; M K B Parmar; C Amos; C Murray; W Qian
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

View more
  7 in total

1.  Overuse of external beam radiotherapy for stage I endometrial cancer.

Authors:  Jason D Wright; Benjamin Margolis; June Y Hou; William M Burke; Ana I Tergas; Yongmei Huang; Jim C Hu; Cande V Ananth; Alfred I Neugut; Dawn L Hershman
Journal:  Am J Obstet Gynecol       Date:  2016-02-11       Impact factor: 8.661

2.  Cervical cancer treated with reduced-volume intensity-modulated radiation therapy base on Sedlis criteria (NCCN VS RTOG).

Authors:  Hua-Chun Luo; Gui-Shan Lin; Shao-Guang Liao; Feng-Mei Wang; Hui-Hua Cheng; Jing Feng; Qin Yin; Qun-Hua Chen; Jin-Feng Zhu; Jian-Feng Xu; Dian Wang; Zhi-Chao Fu
Journal:  Br J Radiol       Date:  2017-12-05       Impact factor: 3.039

3.  Comparing long-term treatment-associated toxicities in cancer patients: approaches, caveats, and recommendations.

Authors:  Matthew J Schipper; Jeremy M Taylor; Grace L Smith; Reshma Jagsi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-05       Impact factor: 7.038

4.  A surveillance study of intensity-modulated radiation therapy for postoperative cervical cancer in Japan.

Authors:  Naoya Murakami; Hiroyuki Okamoto; Fumiaki Isohashi; Keiko Murofushi; Tatsuya Ohno; Daisaku Yoshida; Makoto Saito; Koji Inaba; Yoshinori Ito; Takafumi Toita; Jun Itami
Journal:  J Radiat Res       Date:  2015-04-09       Impact factor: 2.724

Review 5.  Major clinical research advances in gynecologic cancer in 2013.

Authors:  Dong Hoon Suh; Jae-Weon Kim; Sokbom Kang; Hak Jae Kim; Kyung-Hun Lee
Journal:  J Gynecol Oncol       Date:  2014-07-03       Impact factor: 4.401

6.  Dosimetric benefits of intensity-modulated radiotherapy and volumetric-modulated arc therapy in the treatment of postoperative cervical cancer patients.

Authors:  Xia Deng; Ce Han; Shan Chen; Congying Xie; Jinling Yi; Yongqiang Zhou; Xiaomin Zheng; Zhenxiang Deng; Xiance Jin
Journal:  J Appl Clin Med Phys       Date:  2016-11-21       Impact factor: 2.102

7.  Intensity-Modulated Radiation Therapy Versus 3D Conformal Radiotherapy for Postoperative Gynecologic Cancer: Are They Covering the Same Planning Target Volume?

Authors:  Jelena Lukovic; Nikhilesh Patil; David D'souza; Barbara Millman; Brian P Yaremko; Eric Leung; Frances Whiston; George Hajdok; Eugene Wong
Journal:  Cureus       Date:  2016-01-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.